These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 38950555

  • 1. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
    Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT.
    Lancet Oncol; 2024 Aug; 25(8):1015-1024. PubMed ID: 38950555
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).
    Nakaigawa N, Hasumi H, Utsunomiya D, Yoshida K, Ishiwata Y, Oka T, Hayward C, Makiyama K.
    Jpn J Clin Oncol; 2024 Aug 14; 54(8):873-879. PubMed ID: 38864246
    [Abstract] [Full Text] [Related]

  • 10. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, Hill GC, Jacobs PM, Tatum JL, Doroshow JH, Kalen JD.
    Nucl Med Biol; 2013 May 14; 40(4):451-7. PubMed ID: 23454247
    [Abstract] [Full Text] [Related]

  • 11. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Korsen JA, Gutierrez JA, Tully KM, Carter LM, Samuels ZV, Khitrov S, Poirier JT, Rudin CM, Chen Y, Morris MJ, Bodei L, Pillarsetty N, Lewis JS.
    Proc Natl Acad Sci U S A; 2022 Jul 05; 119(27):e2203820119. PubMed ID: 35759660
    [Abstract] [Full Text] [Related]

  • 12. A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo.
    Tang Y, Hu Y, Liu W, Chen L, Zhao Y, Ma H, Yang J, Yang Y, Liao J, Cai J, Chen Y, Liu N.
    Nucl Med Biol; 2019 Mar 05; 70():23-31. PubMed ID: 30826708
    [Abstract] [Full Text] [Related]

  • 13. 89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.
    Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS.
    J Nucl Med; 2017 Sep 05; 58(9):1386-1394. PubMed ID: 28280216
    [Abstract] [Full Text] [Related]

  • 14. Total-Body PET and Highly Stable Chelators Together Enable Meaningful 89Zr-Antibody PET Studies up to 30 Days After Injection.
    Berg E, Gill H, Marik J, Ogasawara A, Williams S, van Dongen G, Vugts D, Cherry SR, Tarantal AF.
    J Nucl Med; 2020 Mar 05; 61(3):453-460. PubMed ID: 31562219
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.
    O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G, Lyashchenko SK, Williams SP, Scher HI, Fine BM, Humm JL, Larson SM, Morris MJ, Carrasquillo JA.
    Mol Pharm; 2019 Jul 01; 16(7):3083-3090. PubMed ID: 31117485
    [Abstract] [Full Text] [Related]

  • 17. Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies.
    Joraku A, Hatano K, Kawai K, Kandori S, Kojima T, Fukumitsu N, Isobe T, Mori Y, Sakata M, Hara T, Nasu K, Minami M, Iizumi Y, Nishiyama H.
    Ann Nucl Med; 2019 Feb 01; 33(2):119-127. PubMed ID: 30406361
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.